FDA OKs Return of 'Marijuana' Drug
Drug, Called Cesamet, Treats Nausea and Vomiting From Chemo
May 18, 2006 -- The FDA has given marketing approval to the drug Cesamet,
which contains a synthetic cannabinoid. Cannabinoids are the active ingredients
Cesamet treats chemotherapy-related nausea and vomiting in cancer patients who don’t
adequately respond to conventional treatments for nausea and vomiting. The drug
comes in capsules taken by mouth.
The FDA originally approved Cesamet in 1985 when the drug was made by Eli
Lilly and Company. Lilly discontinued the drug in 1989 for commercial reasons,
according to news reports.
Valeant Pharmaceuticals International bought Cesamet from Lilly in 2004 and
currently markets the drug in Canada. Valeant has revised the drug’s labeling
and expects to launch Cesamet in the U.S. “in the next several weeks following
approval,” states a Valeant news release.
About the Drug
The drug’s label states that Cesamet, “like other cannabinoids, has complex
effects on the central nervous system” and that the drug may work by
interacting with cannabinoid receptors (the CB1 receptor) in the brain.
According to Valeant’s news release, Cesamet’s safety and effectiveness was
tested in 11 clinical trials totaling more than 300 cancer chemotherapy
patients. Five trials compared Cesamet with another drug called Compazine
(prochlorperazine) that doesn’t contain cannabinoids. Compazine is a common
medication for nausea and vomiting, especially for cancer patients. The other
six studies compared Cesamet with sugar pills (placebo), which contained no
In all but one study, Cesamet came out on top in all statistical
comparisons, meaning that patients using Cesamet had fewer vomiting episodes
and less severe nausea, states Valeant.
“During clinically controlled trials of Cesamet, virtually all patients
experienced at least one adverse reaction,” states Valeant’s news release.
Patients in those trials who took Cesamet “reported a higher incidence of
adverse effects,” states the drug’s label. “The most frequent were drowsiness,
vertigo, dry mouth, and
euphoria,” the label states. “However, most of these adverse effects occurring
with Cesamet were of mild to moderate severity.”
Cesamet is classified as a “Schedule II” drug, meaning it has a “high
potential for abuse,” states the drug’s label, which includes these notes:
- Cesamet prescriptions should be limited to the amount necessary for a
single cycle of chemotherapy (i.e., a few days).
- Cesamet isn’t intended as a first-line treatment for chemo-related nausea
- Prescribers should monitor patients for signs of excessive use, abuse, and
- Patients should be specifically warned not to drive, operate machinery, or
engage in any hazardous activity while taking Cesamet.
- Cesamet shouldn’t be taken with alcohol, sedatives, hypnotics, or other
- Patients taking Cesamet should be supervised by a responsible adult,
especially during initial use and dose adjustments.